Liberty’s Expeditionary Science and Special Programs Division (ESSPD) develops bioengineering and clinical solutions to challenging medical, commercial and industrial unmet needs. These solutions are derived from novel organisms obtained from government and Liberty's own proprietary collection of extremophile biologics. ESSPD's multidisciplinary team of microbiologists and bioinformaticians are supported by physicians and experts drawn from military and intelligence communities.
Bioengineering lead candidate (LJ-182M)
Through an exclusive agreement with NASA’s Jet Propulsion Laboratory, ESSPD has privileged access to organisms that have survived under simulated Mars and Deep-Space environments. For more than 40-years, JPL has screened and catalogued these organisms, providing ESSPD with isolates that exhibit unique biological characteristics that have potential clinical or industrial applicability. Part of this portfolio is comprised of isolates derived from the exterior of low-Earth orbiting satellites and other space platforms.
One novel species, designated as LJ-182M, is capable of surviving sustained exposure to high-doses of UV radiation that otherwise destroy the DNA of species on Earth. ESSPD scientists have forced directed evolution of LJ-182M to produce UV-resistant compounds. These compounds are being characterized for UV-blocking biological capabilities for use in hydrogels, paints, plastics, and other industrial and commercial materials.
Clinical lead candidate (LP-888)
ESSPD is developing another novel organism, designated as LP-888, that secretes a compound that inhibits bacterial efflux pumps. Efflux pumps serve as the principal pathway used by bacteria to develop resistance to antibiotics. The compound produced by LP-888 has been shown to reverse antibiotic resistance in a range of human pathogens, to include Methicillin-resistant Staphylococcus aureus (MRSA). LP-888 is under investigation by EESPD as a co- therapeutic to antibiotics to enhance their effectiveness in defeating antibiotic resistant strains of bacteria.
Liberty BioSecurity is a privately-owned life sciences company and founding member of the Eden Roc Sciences Family of Companies. Liberty develops solutions to the most challenging problems in biology, national security, and human health. Liberty is headquartered in Virginia with laboratories and offices in Massachusetts, Florida, Thailand and Australia.